Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine (VCIV) to Prevent Culture Confirmed Influenza Infection (CCII).

Trial Profile

Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine (VCIV) to Prevent Culture Confirmed Influenza Infection (CCII).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2009

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 12 Aug 2009 Actual patient number (3670) added as reported by ClinicalTrials.gov.
    • 01 Dec 2008 Dec 2008 added as the actual completion date, based on information from ClinicalTrials.gov.
    • 01 Dec 2008 Status changed from recruiting to completed, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top